HC Wainwright Predicts Higher Earnings for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities researchers at HC Wainwright upped their Q1 2027 EPS estimates for Rockwell Medical in a report issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.01 for the quarter, up from their prior estimate of ($0.01). HC Wainwright has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for Rockwell Medical’s FY2027 earnings at $0.05 EPS.

A number of other analysts have also issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Rockwell Medical in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $2.00.

Rockwell Medical Stock Up 0.6%

Shares of NASDAQ RMTI opened at $0.84 on Tuesday. Rockwell Medical has a 1 year low of $0.74 and a 1 year high of $2.10. The firm’s 50 day moving average price is $0.92 and its 200 day moving average price is $0.96. The firm has a market cap of $33.09 million, a P/E ratio of -5.59 and a beta of 1.65. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.63 and a current ratio of 3.98.

Rockwell Medical (NASDAQ:RMTI) last announced its earnings results on Thursday, May 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). Rockwell Medical had a negative return on equity of 15.53% and a negative net margin of 7.98%.The firm had revenue of $17.34 million for the quarter, compared to analyst estimates of $17.95 million.

Hedge Funds Weigh In On Rockwell Medical

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after purchasing an additional 148,737 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after purchasing an additional 41,668 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Rockwell Medical in the 4th quarter valued at $84,000. XTX Topco Ltd boosted its holdings in shares of Rockwell Medical by 286.5% in the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after purchasing an additional 46,029 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in shares of Rockwell Medical by 635.1% in the 3rd quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after purchasing an additional 141,672 shares during the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware?domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.